David P Nicolau
Overview
Explore the profile of David P Nicolau including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
612
Citations
7331
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Fouad A, Nicolau S, Tamma P, Simner P, Nicolau D, Gill C
Infect Dis (Lond)
. 2025 Mar;
:1-11.
PMID: 40042366
Background: with difficult-to-treat resistance is a clinical burden. Ceftolozane/tazobactam is recommended for difficult-to-treat although cefiderocol represents an option due to its potency against isolates with ceftolozane/tazobactam-resistance. Head-to-head data assessing these...
2.
Koenig C, Fratoni A, Abouelhassan Y, Gluck J, Nicolau D, Kuti J
Int J Antimicrob Agents
. 2025 Feb;
65(5):107465.
PMID: 39971141
Objective: Critical illness and organ support such as extracorporeal membrane oxygenation (ECMO) may influence antimicrobial pharmacokinetics. This study investigated cefiderocol pharmacokinetics in critically-ill patients receiving ECMO to understand if standard...
3.
Abouelhassan Y, Kuti J, Nicolau D, Abdelraouf K
JAC Antimicrob Resist
. 2024 Dec;
6(6):dlae203.
PMID: 39712636
Background: Sulbactam is an effective therapy for infections. Previous sulbactam pharmacokinetics/pharmacodynamics (PK/PD) analyses established exposure efficacy targets in plasma against pneumonia. Herein, we established sulbactam efficacy targets in epithelial lining...
4.
Fratoni A, Padgett A, Roenfanz H, Duffy E, Nicolau D
J Antimicrob Chemother
. 2024 Dec;
80(2):478-484.
PMID: 39657022
Background: Murine pneumonia models play a fundamental role in the preclinical development of novel compounds seeking an indication for the treatment of pneumonia. It is vital that plasma exposures in...
5.
Koenig C, Monogue M, Shields R, Sakon C, Fratoni A, Roenfanz H, et al.
Antimicrob Agents Chemother
. 2024 Dec;
69(1):e0153924.
PMID: 39655913
Persons with CF (pwCF) present altered pharmacokinetics (PK) and are often infected with multidrug-resistant (MDR) bacteria. Herein, we describe the PK of cefiderocol, a siderophore cephalosporin with potent activity against...
6.
Abouelhassan Y, Shen Y, Chen A, Ye X, Nicolau D, Kuti J
Antimicrob Agents Chemother
. 2024 Dec;
69(1):e0167423.
PMID: 39655912
Sulbactam-durlobactam is approved for the treatment of hospital-acquired and ventilator-associated bacterial pneumonia caused by susceptible isolates of complex. Patients with serious infections may require support with continuous renal replacement therapy...
7.
Buyukyanbolu E, Gill C, Genc L, Karakus M, Comert F, Otlu B, et al.
Eur J Clin Microbiol Infect Dis
. 2024 Nov;
44(1):159-165.
PMID: 39546100
Introduction: Although CRPA may test susceptible to other β-lactams such as ceftazidime (CAZ), cefepime (FEP), and piperacillin/tazobactam (TZP), reduced potency has been observed. We assessed the adequacy of EUCAST Susceptible...
8.
Fratoni A, Padgett A, Duffy E, Nicolau D
J Antimicrob Chemother
. 2024 Oct;
80(1):154-161.
PMID: 39475376
Background: Preclinical murine infection models lack inter-laboratory uniformity, complicating result comparisons and data reproducibility. The European Innovative Medicines initiative-funded consortium (COMBINE) has developed a standardized murine neutropenic pneumonia protocol to...
9.
Fouad A, Nicolau S, Tamma P, Simner P, Nicolau D, Gill C
J Antimicrob Chemother
. 2024 Oct;
79(12):3236-3242.
PMID: 39442926
Background: Bacterial persistence is a phenomenon whereby a subpopulation of bacteria survive high concentrations of an active antibiotic in the absence of phenotypic alterations. Persisters are associated with chronic and...
10.
Fouad A, Kobic E, Nicolasora N, Thompson Bastin M, Adams P, Shen Y, et al.
Open Forum Infect Dis
. 2024 Oct;
11(10):ofae451.
PMID: 39435320
Background: Cefiderocol is the first antibiotic with effluent flow rate-based dosing recommendations outlined in the product label for patients receiving continuous renal replacement therapy (CRRT). We aimed to investigate the...